Department of Obstetrics and Gynecology, Division of Minimally Invasive Gynecology, Christiana Care Health Systems, Newark, Delaware (Drs. Huynh, Patel, and Makai); Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania (Dr. Goldstein).
Department of Obstetrics and Gynecology, Division of Minimally Invasive Gynecology, Christiana Care Health Systems, Newark, Delaware (Drs. Huynh, Patel, and Makai); Department of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania (Dr. Goldstein).
J Minim Invasive Gynecol. 2021 Feb;28(2):237-244.e2. doi: 10.1016/j.jmig.2020.04.040. Epub 2020 May 8.
To evaluate whether a single dose of gabapentin given preoperatively reduces narcotic use 24 hours after minimally invasive hysterectomy (MIH).
Randomized controlled trial.
Single academic-affiliated community hospital.
Women undergoing MIH for benign indications between June 2016 and June 2017.
Subjects were randomized to receive a preoperative regimen of acetaminophen, celecoxib, and gabapentin versus acetaminophen and celecoxib alone.
The primary outcome assessed was the total amount of narcotics used at 24 hours after surgery. Secondary outcomes included adverse effects from gabapentin use, total narcotics used, and pain scores at 2 weeks after surgery. A total of 129 women were randomized and eligible for analysis in the gabapentin study arm (n = 68) or the control arm (n = 61). Demographic characteristics and surgical details were similar between groups. Narcotics used at 24 hours after surgery totaling 168 versus 161 oral morphine milligram equivalents in the gabapentin and control groups, respectively, did not significantly differ between groups (p = .60). Total narcotics used and pain scores at 2 weeks after surgery and the rates of adverse effects from gabapentin were also similar between study arms.
Single-dose, preoperative gabapentin for women undergoing benign MIH does not reduce total opioid use 24 hours after surgery.
评估在微创子宫切除术(MIH)前给予单次剂量加巴喷丁是否能减少术后 24 小时内的阿片类药物使用。
随机对照试验。
单家学术附属社区医院。
2016 年 6 月至 2017 年 6 月间因良性指征接受 MIH 的女性。
受试者随机接受术前给予扑热息痛、塞来昔布和加巴喷丁治疗方案或仅给予扑热息痛和塞来昔布治疗。
主要结果评估是术后 24 小时内使用的阿片类药物总量。次要结果包括加巴喷丁使用的不良反应、总阿片类药物使用量和术后 2 周的疼痛评分。共有 129 名女性被随机分配至加巴喷丁研究组(n=68)或对照组(n=61),并符合分析条件。组间的人口统计学特征和手术细节相似。术后 24 小时内使用的阿片类药物总量,加巴喷丁组为 168 个口服吗啡毫克当量,对照组为 161 个,两组间无显著差异(p=0.60)。两组间术后 2 周的总阿片类药物使用量和疼痛评分以及加巴喷丁不良反应的发生率也相似。
对于接受良性 MIH 的女性,单次术前给予加巴喷丁并不能减少术后 24 小时内的总阿片类药物使用量。